Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNC for Adult Severe TBI
NCT02525432Phase 2Active, not recruiting
- Sponsor
- UTHealth Houston
- Start
- Nov 2016
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ceva101 in traumatic brain injury (TBI), sponsored by UTHealth Houston. Started Nov 2016; status: active, not recruiting.
02
Drugs
ceva101
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02525432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525432.